REMARKS

The purpose of the forgoing Amendment is to submit the Abstract on a single separate sheet and to delete multiple dependent claims, placing the application in better form for examination under U.S. practice. No new matter is entered.

Respectfully submitted,

TPP/mat

Attorney Docket No.: TPP 31440

Thomas P. Pavelko Registration No. 31,689

STEVENS, DAVIS, MILLER & MOSHER, L.L.P.

1615 L Street, N.W., Suite 850 Washington, D.C. 20036

Telephone: (202) 785-0100

Facsimile: (202) 408-5200 or (202) 408-5088

Date: March 14, 2002

ATTACHMENT I

ABSTRACT

The present invention relates to the IGS3 G-protein coupled receptor family, and to polynucleotides encoding said IGS3 proteins. The invention also relates to inhibiting or activating the action of such polynucleotides and polypeptides, to a vector containing said polynucleotides, a host cell conaining such vector and non-human transgenic animals where the IGS3-gene is either overexpressed, misexpressed, underexpressed or suppressed (knock-out animals). The invention further relates to a method for screening compounds capable to act as an agonist or an antagonist of said G-protein coupled receptor family IGS3 and the use of IGS3 polypeptides and polynucleotides and agonists or antagonists to the IGS3 receptor family in the treatment of a broad range of disorders and diagnostic assays for such conditions.

ATTACHMENT II

- 5. (Amended) The polynucleotide of claim 1[-4], which is DNA or RNA.
- 10. (Amended) IGS3 receptor membrane preparation derived from a cell according to claim 7[-9].